Company Page
Breakthru Medicine
Founders
Breakthru Medicine is a biotechnology company developing disruptive therapeutic modalities for cancer patients to address major unmet medical needs. The company emerged from stealth in January 2026 with a multi-modality platform spanning small molecules, molecular glues, and novel antibody-drug conjugate payloads. Founded by biotech industry veterans Steve Potts, PhD (CEO), Mark Mulvihill, PhD (CSO), and Brian Barnett, MD, the company takes a patient-first, tumor-agnostic targeting approach with an explicit goal of expanding the druggable target universe for difficult-to-treat cancers. The team brings a track record spanning companion diagnostics, targeted oncology drugs, first-in-class molecular glue programs, and multiple INDs, Phase 1 programs, pivotal studies, and commercial launches.
Company Founded in 2026
Healthtech & Biotech